SUPERNUS PHARMACEUTICALS, INC. — Form 8-K
Filed November 2, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 78/100
What the filing says
Supernus Pharmaceuticals received a notice of delisting or failure to satisfy continued listing standards on November 2, 2026. The filing indicates Item 3.01 was triggered, concerning notice of delisting or transfer of listing. No specific reason, cure period, or remedial actions are detailed in the header information provided.
Why this rating
Delisting threatens market access and liquidity for a $1.7B public company, materially impairing shareholder value and financing capability despite lacking cure details here.
Extracted items
Tradability signal
SHORT
conviction 29/100 · expected -0.47% over 4 hrs
SHORT (drift): bad news keeps sliding after dissemination — our one persistent measured edge. Similar past filings (70 in this cell) moved +0.64% in the called direction over 4 hrs; shrunk for sample size that's a +0.47% edge. Exit plan: HARD stop 5% against entry — default width (volatility unmeasured), fixed, not trailing (trails test terribly on these names) — time exit 4 hrs.
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it negative)
at our read · unknown $41.92 | +10 min · unknown $41.92 ▲ 0.00% | +30 min · unknown $41.92 ▲ 0.00% | +1 hr · unknown $41.92 ▲ 0.00% | +4 hrs pending |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from November 2, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.